Aerovate Therapeutics Operating Income

Aerovate Therapeutics (AVTE) currently reports a operating income of $-180M as of June 2026. That compares with $-55M in the prior-year period — down 236.0% year over year. Use the charts on this page to explore Aerovate Therapeutics's operating income history and peer comparisons.

Aerovate Therapeutics's operating income decreased from $-55M to $-180M — a 236.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aerovate Therapeutics reported $-180M in operating income as of June 2026. That compares with $-55M in the prior-year period — down 236.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-180M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aerovate Therapeutics, and consider following AVTE for alerts when major investors trade the stock.

Aerovate Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $-180M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AVTE with unrelated industries.